143 related articles for article (PubMed ID: 18221310)
1. Rhodanine derivatives as selective protease inhibitors against bacterial toxins.
Johnson SL; Chen LH; Harbach R; Sabet M; Savinov A; Cotton NJ; Strongin A; Guiney D; Pellecchia M
Chem Biol Drug Des; 2008 Feb; 71(2):131-9. PubMed ID: 18221310
[TBL] [Abstract][Full Text] [Related]
2. Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors.
Jiao GS; Cregar L; Goldman ME; Millis SZ; Tang C
Bioorg Med Chem Lett; 2006 Mar; 16(6):1527-31. PubMed ID: 16386899
[TBL] [Abstract][Full Text] [Related]
3. Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies.
Johnson SL; Jung D; Forino M; Chen Y; Satterthwait A; Rozanov DV; Strongin AY; Pellecchia M
J Med Chem; 2006 Jan; 49(1):27-30. PubMed ID: 16392787
[TBL] [Abstract][Full Text] [Related]
4. Combating the threat of anthrax: a quantitative structure-activity relationship approach.
Verma RP; Hansch C
Mol Pharm; 2008; 5(5):745-59. PubMed ID: 18611038
[TBL] [Abstract][Full Text] [Related]
5. Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin.
Karginov VA; Yohannes A; Robinson TM; Fahmi NE; Alibek K; Hecht SM
Bioorg Med Chem; 2006 Jan; 14(1):33-40. PubMed ID: 16169738
[TBL] [Abstract][Full Text] [Related]
6. Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.
Jiao GS; Simo O; Nagata M; O'Malley S; Hemscheidt T; Cregar L; Millis SZ; Goldman ME; Tang C
Bioorg Med Chem Lett; 2006 Oct; 16(19):5183-9. PubMed ID: 16870442
[TBL] [Abstract][Full Text] [Related]
7. Yeast-hybrid based high-throughput assay for identification of anthrax lethal factor inhibitors.
Kim J; Park HC; Gedi V; Park HY; Roberts AG; Atkins WM; Yoon MY
Biochem Biophys Res Commun; 2011 Jan; 404(1):517-22. PubMed ID: 21144836
[TBL] [Abstract][Full Text] [Related]
8. Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.
Schepetkin IA; Khlebnikov AI; Kirpotina LN; Quinn MT
J Med Chem; 2006 Aug; 49(17):5232-44. PubMed ID: 16913712
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic differences between in vitro assays for hydrazone-based small molecule inhibitors of anthrax lethal factor.
Hanna ML; Tarasow TM; Perkins J
Bioorg Chem; 2007 Feb; 35(1):50-8. PubMed ID: 16949126
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of anthrax lethal factor.
Gaddis BD; Avramova LV; Chmielewski J
Bioorg Med Chem Lett; 2007 Aug; 17(16):4575-8. PubMed ID: 17574849
[TBL] [Abstract][Full Text] [Related]
11. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
Xiong Y; Wiltsie J; Woods A; Guo J; Pivnichny JV; Tang W; Bansal A; Cummings RT; Cunningham BR; Friedlander AM; Douglas CM; Salowe SP; Zaller DM; Scolnick EM; Schmatz DM; Bartizal K; Hermes JD; MacCoss M; Chapman KT
Bioorg Med Chem Lett; 2006 Feb; 16(4):964-8. PubMed ID: 16338135
[TBL] [Abstract][Full Text] [Related]
12. Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity.
Choi J; Ko Y; Lee HS; Park YS; Yang Y; Yoon S
Eur J Med Chem; 2010 Jan; 45(1):193-202. PubMed ID: 19879669
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.
Johnson SL; Chen LH; Barile E; Emdadi A; Sabet M; Yuan H; Wei J; Guiney D; Pellecchia M
Bioorg Med Chem; 2009 May; 17(9):3352-68. PubMed ID: 19359184
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease.
Burnett JC; Wang C; Nuss JE; Nguyen TL; Hermone AR; Schmidt JJ; Gussio R; Wipf P; Bavari S
Bioorg Med Chem Lett; 2009 Oct; 19(19):5811-3. PubMed ID: 19703771
[TBL] [Abstract][Full Text] [Related]
15. Rhodanine-3-acetic acid derivatives as inhibitors of fungal protein mannosyl transferase 1 (PMT1).
Orchard MG; Neuss JC; Galley CM; Carr A; Porter DW; Smith P; Scopes DI; Haydon D; Vousden K; Stubberfield CR; Young K; Page M
Bioorg Med Chem Lett; 2004 Aug; 14(15):3975-8. PubMed ID: 15225710
[TBL] [Abstract][Full Text] [Related]
16. A high-throughput screening approach to anthrax lethal factor inhibition.
Johnson SL; Chen LH; Pellecchia M
Bioorg Chem; 2007 Aug; 35(4):306-12. PubMed ID: 17320146
[TBL] [Abstract][Full Text] [Related]
17. QSAR and molecular docking studies of lethal factor protease inhibitors against
Saxena M; Nandi S; Saxena AK
SAR QSAR Environ Res; 2019 Oct; 30(10):715-731. PubMed ID: 31556709
[No Abstract] [Full Text] [Related]
18. Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease.
Oost T; Sukonpan C; Brewer M; Goodnough M; Tepp W; Johnson EA; Rich DH
Biopolymers; 2003; 71(6):602-19. PubMed ID: 14991672
[TBL] [Abstract][Full Text] [Related]
19. Stop the killer: how to inhibit the anthrax lethal factor metalloprotease.
Montecucco C; Tonello F; Zanotti G
Trends Biochem Sci; 2004 Jun; 29(6):282-5. PubMed ID: 15276179
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of anthrax lethal factor based upon N-oleoyldopamine.
Gaddis BD; Rubert Pérez CM; Chmielewski J
Bioorg Med Chem Lett; 2008 Apr; 18(7):2467-70. PubMed ID: 18314330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
